查詢結果分析
來源資料
相關文獻
- 慢性骨髓性白血病之進步--治療及疾病監測
- 慢性骨髓性白血病
- 慢性骨髓性白血病的新治療
- 慢性骨髓性白血病治療之最新進展
- Cytogenetic Study of Chronic Myelocytic Leukemia Three Cases with Complex Ph[fec1] Translocation
- 神奇藥丸基立克(Glivec)是否依然神奇?
- 慢性骨髓性白血病藥物治療的進展
- Additional Chromosome Abnormalities in Chronic Myeloid Leukemia
- 慢性骨髓性白血病之費城染色體的新近概念
- Complete Recovery from Dasatinib-Induced Pulmonary Arterial Hypertension after Successful Discontinuation of Tyrosine Kinase Inhibitor in a Case of Chronic Myeloid Leukemia
頁籤選單縮合
題名 | 慢性骨髓性白血病的新治療=A New Treatment in Chronic Myeloid Leukemia |
---|---|
作者 | 石祐安; 李玟勳; 蕭惠娟; 張秀美; 黃微瑄; | 書刊名 | 藥學雜誌 |
卷期 | 34:4=137 2018.12[民107.12] |
頁次 | 頁75-80 |
分類號 | 415.635 |
關鍵詞 | 慢性骨髓性白血病; 酪胺酸激酶抑制劑; 費城染色體; Chronic myeloid leukemia; Tyrosine kinase inhibitors; |
語文 | 中文(Chinese) |
中文摘要 | 慢性骨髓性白血病 (chronic myeloid leukemia,CML) 是骨髓造血細胞增生性疾 病,酪胺酸激酶抑制劑 (tyrosine kinase inhibitors,TKI) 目前為 CML 標靶治療的用藥, imatinib 是第一代 TKI,可有效抑制癌細胞增生,但隨著費城染色體基因突變會產生 抗藥性,因此第二代和第三代 TKI 也相繼問世,如 nilotinib、dasatinib、bosutinib 及 ponatinib,可用於治療新診斷、對 imatinib 有抗藥性或無法耐受之 CML。不同的酪胺酸 激酶抑制劑的突變作用點及副作用皆不同,可依病人特殊治療需求來選擇適合的藥物。 |
英文摘要 | Chronic myeloid leukemia (CML) is a hematopoietic stem cell disease. Tyrosine kinase inhibitors (TKIs) are the initial targeted therapies for CML. Imatinib is the first generation of TKI which has been proven to be effective in BCR-ABL tyrosine kinase. As a result of mutations in the kinase domain of BCR-ABL, the second and the third generation of TKIs have been developed, such as nilotinib, dasatinib, bosutinib, ponatinib. They are approved for the treatment of newly diagnosed or imatinib-resistant or -intolerant CML. There are different selectivities for BCR-ABL, and different side effects for TKIs’. Appropriate medications could be chosen based on the need of patients’ special treatment. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。